Objectives To analyze the expression of miR-122 and evaluate its significance in patients with HBV infection in different phases. Methods Eleven chronic hepatitis B (CHB), 26 hepatitis B virus (HBV)-induced cirrhosis, 16 HBV-associated hepatocellular carcinoma (HCC) patients and 10 healthy control cases were enrolled. The serum levels of miR-122 were detected by RT-PCR and compared between healthy individuals and CHB at different stages. Results Compared with healthy control cases, serum miR-122 levels were markedly increased in HBV infection cases (AUC = 0.795, P =0.002). In the CHB group, miR-122 levels were positively associated with albumin levels ( P < 0.05) but had no significant associations with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ( P > 0.05). In the cirrhosis group, miR-122 expression was remarkably lower in the Child C group in comparison with the Child A group ( P =0.025). At the same time, miR-122 amounts had a negative correlation with HVPG ( P < 0.05). In the HCC group, miR-122 amounts were negatively associated with alkaline phosphatase (AKP) and alpha-fetoprotein (AFP) ( P < 0.05). Serum miR-122 amounts in 3 patients who died were lower than the survival group (5.520 ± 0.522 vs. 5.860 ± 1.183, P > 0.05). Conclusion Serum miR-122 can be leveraged to screen patients with HBV infection. In HBV sufferers, the serum miR-122 expression level is related to liver disease progression, hence making it an underlying molecular biomarker for predicting the development of CHB.
Serum Expression Level of MicroRNA-122 and Its Significance in Patients with Hepatitis B Virus Infection
[Category] B형 간염,
[Article Type] Research Article
[Source] PMC
All Keywords